OrbusNeich Starts China Trial of COMBO™ Dual Therapy Stent

OrbusNeich, headquartered in Hong Kong, has enrolled the first patient in a China clinical trial of its COMBO™ Dual Therapy Stent. The COMBO stent has a coating of anti-CD34 antibodies to promote endothelialization of the stent, combined with sirolimus drug elution to deter the blood vessel from re-closing over the longer term. OrbusNeich, which makes medical devices for the vascular market, has manufacturing facilities in Shenzhen and the Netherlands, plus an R&D operation in Fort Lauderdale, Florida. More details.... Share this with colleagues: // //